Cargando…

A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells

Immune checkpoint inhibitors can block inhibitory molecules on the surface of T cells, switching them from an exhausted to an active state. One of these inhibitory immune checkpoints, programmed cell death protein 1 (PD-1) is expressed on T cell subpopulations in acute myeloid leukemia (AML). PD-1 e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guinn, Barbara-ann, Schuler, Patrick J., Schrezenmeier, Hubert, Hofmann, Susanne, Weiss, Johanna, Bulach, Christiane, Götz, Marlies, Greiner, Jochen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253334/ https://www.ncbi.nlm.nih.gov/pubmed/37298237 http://dx.doi.org/10.3390/ijms24119285

Ejemplares similares

P477: COMBINATION OF DIFFERENT IMMUNOTHERAPEUTIC DRUGS ENHANCES SPECIFIC T CELL IMMUNE RESPONSES AGAINST LEUKEMIC CELLS AND LEUKEMIC PROGENITOR/STEM CELLS IN ACUTE MYELOID LEUKEMIA
por: Greiner, Jochen, et al.
Publicado: (2023)

Leukemia Associated Antigens: Their Dual Role as Biomarkers and Immunotherapeutic Targets for Acute Myeloid Leukemia
por: Guinn, Barbara-ann, et al.
Publicado: (2007)

Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients
por: Greiner, Jochen, et al.
Publicado: (2019)

Immunogenic Targets for Specific Immunotherapy in Multiple Myeloma
por: Zhang, Lu, et al.
Publicado: (2012)

TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment
por: Depreter, Barbara, et al.
Publicado: (2020)

Characteristics and mechanisms to control a COVID‐19 outbreak on a leukemia and stem cell transplantation unit
por: Greiner, Jochen, et al.
Publicado: (2020)

The Important Role of Immunotherapies in Acute Myeloid Leukemia
por: Greiner, Jochen
Publicado: (2019)

A Direct Comparison, and Prioritisation, of the Immunotherapeutic Targets Expressed by Adult and Paediatric Acute Myeloid Leukaemia Cells: A Systematic Review and Meta-Analysis
por: Morris, Vanessa S., et al.
Publicado: (2023)

Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target
por: Alatrash, Gheath, et al.
Publicado: (2016)

Lenalidomide and Chronic Lymphocytic Leukemia
por: González-Rodríguez, Ana Pilar, et al.
Publicado: (2013)

DNA Damage and DNA Damage Response in Chronic Myeloid Leukemia
por: Popp, Henning D., et al.
Publicado: (2020)

Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses
por: Schmitt, Michael, et al.
Publicado: (2017)

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia
por: Medeiros, Bruno C., et al.
Publicado: (2018)

Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis
por: Xie, Chun-Hong, et al.
Publicado: (2018)

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia
por: Kenealy, Melita, et al.
Publicado: (2019)

Lenalidomide in the Treatment of Chronic Lymphocytic Leukemia
por: Cortelezzi, Agostino, et al.
Publicado: (2012)

Increasing Role of Targeted Immunotherapies in the Treatment of AML
por: Greiner, Jochen, et al.
Publicado: (2022)

Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome
por: Pham, Brian, et al.
Publicado: (2021)

Cyclosporine Broadens the Therapeutic Potential of Lenalidomide in Myeloid Malignancies
por: Dou, Aixia, et al.
Publicado: (2020)

Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size
por: Berthon, Celine, et al.
Publicado: (2020)

Potential Immunotherapeutic Targets on Myeloid Cells for Neurovascular Repair After Ischemic Stroke
por: Zhu, Ziyu, et al.
Publicado: (2019)

Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia
por: Jain, Prachi, et al.
Publicado: (2017)

Lenalidomide Combined with Interferon α-1b and Interleukin-2 in the Treatment of 21 Cases of Acute Myeloid Leukemia
por: Cheng, Cheng, et al.
Publicado: (2021)

Improving the Outcome of Leukemia by Natural Killer Cell-Based Immunotherapeutic Strategies
por: Chouaib, Salem, et al.
Publicado: (2014)

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
por: Platzbecker, U, et al.
Publicado: (2013)

Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia
por: Craddock, Charles, et al.
Publicado: (2019)

Azacitidine and lenalidomide combination: a novel relapse prophylaxis regimen after allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia
por: Feng, Yimei, et al.
Publicado: (2023)

Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide
por: Negoro, Eiju, et al.
Publicado: (2016)

Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment
por: Gbolahan, Olumide Babajide, et al.
Publicado: (2017)

Immunotherapeutic potential of varicella vaccine in smoldering and cutaneous adult T-cell leukemia/lymphoma
por: Amano, M, et al.
Publicado: (2014)

Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
por: Hofmann, Susanne, et al.
Publicado: (2019)

Survivin’ Acute Myeloid Leukaemia—A Personalised Target for inv(16) Patients
por: Greiner, Jochen, et al.
Publicado: (2021)

Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial
por: Schroeder, Thomas, et al.
Publicado: (2023)

Challenges and Opportunities for Immunotherapeutic Intervention against Myeloid Immunosuppression in Glioblastoma
por: Exley, Mark A., et al.
Publicado: (2022)

Favorable outcomes of DDX41‐mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide
por: Tiong, Ing S., et al.
Publicado: (2023)

Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges
por: Perutelli, Francesca, et al.
Publicado: (2022)

Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal
por: Geyer, Mark B., et al.
Publicado: (2023)

IRX-2, a Novel Immunotherapeutic, Enhances Functions of Human Dendritic Cells
por: Schilling, Bastian, et al.
Publicado: (2013)

Separase activity distribution can be a marker of major molecular response and proliferation of CD34(+) cells in TKI-treated chronic myeloid leukemia patients
por: Spiess, Birgit, et al.
Publicado: (2020)

Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapy
por: Oka, Satoko, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jf1r4id11ath6e4bibsh2gcdco